KRAS and non-small cell lung carcinoma: The authors concluded that STK11–KRAS co-mutations confer a poor prognosis in NSCLC, regardless of treatment class, and that these co-mutations were enriched for negative PD-L1 staining (75.8% vs. 60.8%, p < 0.001) [62].